Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-006 immunotherapy for hospitalized COVID-19
NCT04464395Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mupadolimab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Corvus Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 30 days and Immunoglobulin Anti-SARS CoV-2 Levels at Day 28. Started Jul 2020; status: completed.
02
Drugs
mupadolimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04464395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464395.